Hanmi Pharmaceutical's local subsidiary in China, Beijing Hanmi Pharmaceutical, topped 400 billion won in annual revenue for the first time last year.
Despite price controls and intensifying competition in China's pharmaceutical market, it is being assessed as maintaining a stable revenue structure and strengthening its role as a funding source for Hanmi Pharmaceutical's research and development (R&D) investment.
Hanmi Pharmaceutical said on May 8 that Beijing Hanmi Pharmaceutical Co. (hereafter Beijing Hanmi) posted 402.4 billion won in sales and 77.7 billion won in operating profit in 2025. It is the first time since its 1996 founding that Beijing Hanmi has exceeded 400 billion won in annual revenue.
Beijing Hanmi is a Chinese subsidiary in which Hanmi Pharmaceutical holds 73.68% equity. Hanmi Pharmaceutical received about 9 billion won in dividends from Beijing Hanmi last year, and cumulative dividends since 2009 amount to about 138 billion won.
This year's regular dividend was set at a total of 38.5 billion won (175 million yuan) by applying a 50% payout ratio based on net profit. Of that, about 28.4 billion won was attributed to Hanmi Pharmaceutical. The company said the dividend funds are being used for innovative new drug research and development and global business expansion.
Beijing Hanmi is pursuing production process efficiency and cost-reduction strategies in response to the expansion of the Chinese government's volume-based procurement (VBP) policy for pharmaceuticals. It currently operates a sales and marketing network covering more than 9,000 hospitals and over 200,000 medical professionals across China.
Key products include the constipation drug "Lidong," the antitussive and expectorant "Yi'anping," and the cough and phlegm medicine "Yitanzing." Recently, it has been pushing to expand its portfolio beyond a pediatrics and respiratory-focused business structure into chronic disease areas such as hypertension and diabetes.
A Beijing Hanmi Pharmaceutical official said, "We are building a stable growth foundation through product strategies tailored to the local market and operational efficiency," and added, "We will continue to contribute to strengthening the group's global competitiveness."